Manual screening can quietly become one of the biggest risks in oncology trial recruitment.
Oncology studies are complex by nature.
Eligibility criteria can involve diagnosis history, staging, biomarkers, prior lines of therapy, lab values, imaging, comorbidities and treatment timelines. When screening depends only on manual review, the risk is not just slow recruitment. The bigger risk is missing eligible patients who may never be identified in time.
That is where oncology trials often begin to lose momentum.
A patient may technically qualify, but remain hidden inside fragmented records. A site team may be overwhelmed by chart review. A sponsor may see recruitment delays without realizing that the screening process itself is creating the bottleneck.
In oncology research, every missed patient matters.
Better screening is not just about speed. It is about accuracy, visibility and giving clinical teams the ability to find the right patients before opportunity is lost.
Read the full blog here: https://kitsa.ai/blog/manual-screening-fails-oncology
#ClinicalTrials #ClinicalResearch #OncologyResearch #PatientScreening #PatientRecruitment #ClinicalTrialRecruitment #AIinHealthcare #ClinicalOperations #LifeSciences #HealthcareInnovation #KITSA
